$0.746
+0.015 (+2.07%)收盘时
BRNS 同业对比
In the context of the broader market, BRNS competes directly with industry leaders such as NNVC and ATNM. With a market capitalization of $28.86M, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against NNVC's N/A and ATNM's 100.00%. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
Barinthus Biotherapeutics PLC 财务表现
The company has reported substantial net losses, including -$10.58 million in Q2 2026 and a negative EPS of -0.26. However, it has a strong gross margin of 100% in Q3 2024, but this has not been sustained in recent quarters.
Financials
FY2025Q4
0.00
Total Revenue
FY2026Q2
YoY:
-56.62%
-10.12M
Operating Profit
FY2026Q2
YoY:
-49.83%
-10.60M
Net Income after Tax
FY2026Q2
YoY:
-50.00%
-0.26
EPS - Diluted
FY2026Q2
YoY:
-55.40%
-8.09M
Free Cash Flow
FY2024Q4
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY:
-98.84%
-217.84
FCF Margin - %
FY2024Q4
YoY:
-95.54%
-408.73
Net Margin - %
FY2022Q4
2.20
ROIC
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。